Acadian Asset Management
BHVN

Acadian Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Acadian Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1
Closed – – 2199
2019
Q3 		$0 Buy
+1
New +$42 ﹤0.01% 2118

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management's BHVN Position: Q4 2019 in Review

Acadian Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2019, closing a stake of 1 share.

Acadian Asset Management first reported a position in BHVN in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 188 funds tracked by Wall St. Rank hold BHVN as of Q4 2019.

  • Acadian Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2019 after selling out during the quarter.
  • Acadian Asset Management sold 1 Biohaven Pharmaceutical Holding Company Ltd. share in Q4 2019.
  • Acadian Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 1 quarter.
  • Acadian Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $0 in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2019.

Based on Acadian Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.